Advertisement

Advertisement

DMAC Stock Latest News

Diamedica Therapeutics Balances Trial Momentum and Cash

Company AnnouncementsDiamedica Therapeutics Balances Trial Momentum and Cash

DM199: Encouraging Phase 2 Preeclampsia Data and Disease‑Modifying Potential Support Buy Rating and $12 Price Target

PremiumRatings

DM199: Encouraging Phase 2 Preeclampsia Data and Disease‑Modifying Potential Support Buy Rating and $12 Price Target

13d ago

DiaMedica Expands Equity Incentive Pool With New S-8 Share Registration

PremiumCompany Announcements

DiaMedica Expands Equity Incentive Pool With New S-8 Share Registration

13d ago

DiaMedica Advances Key Phase 2 Programs and Extends Cash Runway Through 2027

PremiumCompany Announcements

DiaMedica Advances Key Phase 2 Programs and Extends Cash Runway Through 2027

13d ago

DiaMedica Therapeutics reports Q2 EPS (19c), consensus (20c)

PremiumThe Fly

DiaMedica Therapeutics reports Q2 EPS (19c), consensus (20c)

14d ago

Is DMAC a Buy, Before Earnings?

PremiumPre-EarningsIs DMAC a Buy, Before Earnings?

16d ago

DiaMedica Therapeutics announces dosing of first two patients in DM199 study

The Fly

DiaMedica Therapeutics announces dosing of first two patients in DM199 study

2M ago

DiaMedica Therapeutics receives written response from FDA on DM199

The Fly

DiaMedica Therapeutics receives written response from FDA on DM199

2M ago

DiaMedica Shareholders Approve Governance, Compensation and Incentive Plan

PremiumCompany Announcements

DiaMedica Shareholders Approve Governance, Compensation and Incentive Plan

3M ago

DiaMedica announces 75% enrollment milestone in ReMEDy2 Phase 2/3 trial

PremiumThe Fly

DiaMedica announces 75% enrollment milestone in ReMEDy2 Phase 2/3 trial

3M ago

DiaMedica Therapeutics Charts Costly Path to Key Trials

PremiumCompany Announcements

DiaMedica Therapeutics Charts Costly Path to Key Trials

4M ago

DiaMedica Therapeutics reports Q1 EPS (19c), consensus (19c)

PremiumThe Fly

DiaMedica Therapeutics reports Q1 EPS (19c), consensus (19c)

4M ago

DiaMedica sees cash, equivalents funding operations through 2027

PremiumThe FlyDiaMedica sees cash, equivalents funding operations through 2027

4M ago

DiaMedica Therapeutics Highlights Clinical Gains Amid Trial Risks

Company Announcements

DiaMedica Therapeutics Highlights Clinical Gains Amid Trial Risks

5M ago

DiaMedica Therapeutics Furnishes 2025 Financial Results and Business Update

Company Announcements

DiaMedica Therapeutics Furnishes 2025 Financial Results and Business Update

5M ago

DiaMedica Therapeutics reports FY25 EPS (70c), consensus (68c)

PremiumThe Fly

DiaMedica Therapeutics reports FY25 EPS (70c), consensus (68c)

5M ago

DMAC Upcoming Earnings Report: What to Expect?

PremiumPre-Earnings

DMAC Upcoming Earnings Report: What to Expect?

5M ago

DiaMedica Therapeutics receives Health Canada clearance to initiate DM199 study

PremiumThe Fly

DiaMedica Therapeutics receives Health Canada clearance to initiate DM199 study

6M ago

Omega takes new stake in Rocket Companies, exits ArriVent Biopharma

PremiumThe Fly

Omega takes new stake in Rocket Companies, exits ArriVent Biopharma

6M ago

DiaMedica Therapeutics Raises Capital via Share Offering

PremiumCompany AnnouncementsDiaMedica Therapeutics Raises Capital via Share Offering

8M ago

DiaMedica Therapeutics named a Top Idea for 2026 at Lake Street

The Fly

DiaMedica Therapeutics named a Top Idea for 2026 at Lake Street

8M ago

DiaMedica Therapeutics provides DM199 update following FDA meeting

The Fly

DiaMedica Therapeutics provides DM199 update following FDA meeting

8M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >